Clinic
UPMC Chautauqua at Wca
UPMC Chautauqua at Wca was paid $6.88M by Medicaid between Jan 2018 and Dec 2024, across 147 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoUPMC CHAUTAUQUA AT WCA
JAMESTOWN, NY 14701
JAMESTOWN, NY 14701
33aNPI1770573222assigned 10/26/2005
33bProvider typeClinic/Center
28Total paid$6.88M
24GClaims116,792
24DCodes billed147
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in New York
Rank by total paid#46 of 235
Median peer was paid$630K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,441 | $36K | |
| 2019 | 9,024 | $266K | |
| 2020 | 18,140 | $842K | |
| 2021 | 18,576 | $906K | |
| 2022 | 21,378 | $1.75M | |
| 2023 | 24,185 | $1.90M | |
| 2024incomplete | 19,048 | $1.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 4,190 | 3,853 | $1.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 2,902 | 2,678 | $1.12M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 12% | 7,490 | 5,068 | $839K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 1,396 | 1,337 | $706K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.1% | 4,014 | 3,376 | $487K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 4.1% | 1,689 | 1,157 | $282K |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 2.8% | 1,076 | 848 | $194K |
| 36415 | Collection of venous blood by venipuncture | 2.5% | 12,963 | 11,048 | $172K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 85 | 85 | $108K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 3,913 | 2,878 | $96K |
| 80053 | Comprehensive metabolic panel | 1.1% | 6,722 | 6,048 | $75K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 1,090 | 1,020 | $70K |
135 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,129 | $64K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,457 | $54K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,344 | $48K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,584 | $42K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,156 | $41K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 548 | $41K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,211 | $34K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 507 | $31K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,233 | $26K |
| Q3014 | Telehealth originating site facility fee | <1% | 461 | $25K |
| 80061 | Lipid panel | <1% | 3,093 | $23K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 448 | $22K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 378 | $21K |
| G0378 | Hospital observation service, per hour | <1% | 27 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,047 | $21K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 990 | $19K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,267 | $18K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 254 | $17K |
| 88342 | <1% | 137 | $17K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 500 | $16K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 187 | $15K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 265 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,455 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,013 | $13K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,307 | $13K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 26 | $11K |
| 73630 | <1% | 501 | $10K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 552 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,334 | $8K |
| 81001 | <1% | 2,392 | $8K | |
| 82607 | <1% | 568 | $7K | |
| 82570 | <1% | 1,963 | $7K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 596 | $7K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,211 | $7K |
| 84439 | <1% | 912 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 130 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 603 | $5K |
| 11721 | <1% | 547 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 127 | $4K |
| 86803 | <1% | 354 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,229 | $4K |
| 83735 | <1% | 1,109 | $4K | |
| 82652 | <1% | 105 | $4K | |
| 73564 | <1% | 155 | $3K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 44 | $3K |
| 87077 | <1% | 441 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $3K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 44 | $3K |
| 74018 | <1% | 298 | $3K | |
| 86701 | <1% | 297 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 64 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 29 | $2K |
| 82746 | <1% | 165 | $2K | |
| 73502 | <1% | 68 | $2K | |
| 83789 | <1% | 463 | $2K | |
| 85610 | <1% | 1,575 | $2K | |
| 84153 | <1% | 150 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 31 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 99 | $2K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 38 | $2K |
| 81003 | <1% | 2,228 | $2K | |
| 87186 | <1% | 357 | $2K | |
| 92557 | <1% | 75 | $2K | |
| 85730 | <1% | 559 | $1K | |
| 88112 | <1% | 29 | $1K | |
| 85027 | <1% | 213 | $995.92 | |
| 72100 | <1% | 51 | $933.40 | |
| 94060 | <1% | 27 | $884.22 | |
| 73030 | <1% | 77 | $870.53 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 61 | $856.52 |
| 87400 | <1% | 289 | $834.68 | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 32 | $798.28 |
| 83970 | <1% | 40 | $784.74 | |
| 73610 | <1% | 46 | $775.71 | |
| 97161 | <1% | 14 | $721.86 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 13 | $720.81 |
| 87510 | <1% | 127 | $717.83 | |
| 82728 | <1% | 66 | $643.39 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 24 | $621.47 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $560.24 |
| 71250 | <1% | 12 | $558.16 | |
| 94729 | <1% | 14 | $554.92 | |
| 83690 | <1% | 1,026 | $548.33 | |
| 87425 | <1% | 100 | $548.13 | |
| 83986 | <1% | 610 | $545.56 | |
| 87070 | <1% | 50 | $529.10 | |
| 94726 | <1% | 14 | $498.93 | |
| 80320 | <1% | 94 | $466.58 | |
| 84100 | <1% | 125 | $463.80 | |
| 84460 | <1% | 79 | $413.16 | |
| 84450 | <1% | 79 | $411.48 | |
| 92567 | <1% | 85 | $404.78 | |
| 84484 | <1% | 1,232 | $403.81 | |
| 83550 | <1% | 54 | $382.81 | |
| 80050 | General health panel | <1% | 69 | $374.36 |
| 76775 | <1% | 25 | $363.00 | |
| 83540 | <1% | 85 | $337.84 | |
| 81025 | <1% | 112 | $332.85 | |
| 87040 | <1% | 74 | $330.58 | |
| 87480 | <1% | 31 | $299.50 | |
| 82962 | <1% | 34 | $283.48 | |
| 87660 | <1% | 31 | $277.05 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 13 | $253.25 |
| 82043 | <1% | 43 | $248.94 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 144 | $223.00 |
| 80076 | <1% | 36 | $181.03 | |
| 84156 | <1% | 53 | $121.59 | |
| 80354 | <1% | 358 | $102.52 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,083 | $99.94 |
| 83880 | <1% | 14 | $98.84 | |
| 84702 | <1% | 15 | $94.09 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 252 | $90.57 |
| 87340 | <1% | 12 | $89.87 | |
| 85651 | <1% | 46 | $82.49 | |
| 86140 | <1% | 13 | $61.23 | |
| 86901 | <1% | 13 | $55.18 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,060 | $53.94 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 33 | $51.82 |
| 86900 | <1% | 13 | $48.86 | |
| 86592 | <1% | 12 | $35.97 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,068 | $22.69 |
| 81015 | <1% | 41 | $4.78 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 32 | $3.75 |
| 84703 | <1% | 14 | $3.74 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 26 | $3.66 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 216 | $3.34 |
| J3490 | Unclassified drugs | <1% | 1,560 | $1.73 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 133 | $0.63 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 68 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 69 | $0.00 |
| 94760 | 0% | 29 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 13 | $0.00 |
| 83605 | 0% | 90 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 69 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDINGER, BRADLEY (CFO)
| Provider | Location | Paid |
|---|---|---|
| UPMC Chautauqua at Wca | Jamestown, NY | $153K |
| UPMC Chautauqua at Wca | Jamestown, NY | $61K |
| UPMC Chautauqua at Wca | Jamestown, NY | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.